论文部分内容阅读
为探讨顺铂化疗中肾毒性的影响，对２４例顺铂治疗的恶性肿瘤患者尿β_２微球蛋白（β_２－ＭＧ）进行监测，并以１０例健康人尿β_２－ＭＧ为正常参考值。结果表明，大剂量组与小剂量组在化疗后同一时间内尿β_２－ＭＧ差异显著（Ｐ＜０．０１）；小剂量Ⅰ组化疗后尿β_２－ＭＧ显著增加（Ｐ＜０．０５）；小剂量Ⅱ组化疗后尿β_２－ＭＧ虽高于正常，但无明显差异（Ｐ＞０．０５）；大剂量Ⅰ组化疗后尿β_２－ＭＧ增加非常显著（Ｐ＜０．０１）；大剂量Ⅱ组化疗后尿β_２－ＭＧ增加，差异非常显著（Ｐ＜０．０１）。提示顺铂小剂量分次给药，大剂量水化及胃复安的应用可明显减低肾毒性。
To investigate the effect of nephrotoxicity in cisplatin chemotherapy, 24 patients with malignant tumors treated with cisplatin were monitored for urinary β2-microglobulin (β 2 -MG), and normal human urine β 2 -MG was taken as the normal reference value. The results showed that the urinary β2-MG was significantly different between the high-dose group and the low-dose group at the same time after chemotherapy (P<0.01), and the urinary β2-MG was significantly increased after the chemotherapy in the low-dose group I (P<0.05). The urine β_2-MG was higher than normal after chemotherapy in low-dose group II, but there was no significant difference (P>0.05). The urinary β_2-MG increased significantly after chemotherapy in high-dose group I (P<0.01); Urinary β_2-MG increased in group II after chemotherapy, with a significant difference (P<0.01). It is suggested that small doses of cisplatin in divided doses, the application of high-dose hydration and metoclopramide can significantly reduce nephrotoxicity.